Source-grounded facts extracted from CV Sciences, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
CV Sciences, Inc. shareholders approved Ratification of Selection of Independent Registered Public Accounting Firm at the 2026-06-02 meeting.
“Proposal 3 - Ratification of Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified Haskell & White LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026, as set forth below: FOR AGAINST ABSTAIN BROKER NON-VOTE 102,384,289 12,488,529 1,361,966 -”
CV Sciences, Inc. shareholders rejected Reverse Stock Split at the 2026-06-02 meeting.
“Proposal 2 - Reverse Stock Split The Company's stockholders did not approve the Company's proposal to amend its Certificate of Incorporation, as amended to effect, at the discretion of the Board of Directors, a reverse stock split of all outstanding shares of common stock at a ratio of not less than 1-for-10 and not greater than 1-for-800, such ratio to be determined by the Board of Directors at any time before May 30, 2029, without further approval or authorization from its stockholders, as set forth below: FOR AGAINST ABSTAIN BROKER NON-VOTE 48,496,747 59,628,926 8,109,111 -”
CV Sciences, Inc. shareholders approved Election of Directors at the 2026-06-02 meeting.
“Proposal 1 - Election of Directors The Company's stockholders elected three directors, each to serve until the Company's next Annual Meeting of Stockholders or until his successor is duly elected and qualified, subject to prior death, resignation or removal, as set forth below: NAME FOR AGAINST ABSTAIN BROKER NON-VOTE Dr. Jamie Corroon 39,505,495 3,183,772 1,078,738 72,466,779 Joseph Dowling 37,674,977 4,813,319 1,279,709 72,466,779 Bill McCorkle 22,671,092 3,928,542 17,168,371 72,466,779”
CV Sciences, Inc. amended senior notes with the Investor maturing July 6, 2027.
“The April Amendment also extended the maturity date of the Third Note to July 6, 2027.”
CV Sciences, Inc. incurred senior notes of $99,614.04 with an institutional investor maturing April 6, 2027.
“On April 6, 2026, the Company issued the Investor a Third Note with a principal amount of $99,614.04.”
CV Sciences, Inc. entered into Third Note with the Investor valued at Principal amount $99,614.04, due April 6, 2027 (later extended) (effective 2026-04-06).
“disclosed, on February 12, 2025, CV Sciences, Inc., a Delaware corporation (the “Company”) entered into a note purchase agreement (the “Original Purchase Agreement”) with an institutional investor (“Investor”), pursuant to which the Company issued and sold to the Investor a secured promissory note in the original principal amount of $1,600,000 (the “Original Note”).”
CV Sciences, Inc. amended April Amendment with the Investor valued at Third Note principal amount $99,614.04; conversion price changed to $0.03 per share; maturity date o (effective 2026-04-09).
“On April 9, 2026, the Company and the Investor entered into an agreement (the "April Amendment") to amend the Notes to implement a new fixed conversion price equal to $0.03 per share.”
CV Sciences, Inc. reported the year and quarter ended December 31, 2025 results: revenue $13.8 million.
“its financial results for the year and quarter ended December 31, 2025. Fiscal 2025, Fourth Quarter 2025 and Recent Financial and Operating Highlights • Generated revenue of $13.8 million for fiscal 2025 compared to $15.7 million for 2024; Revenue of $3.3 million for the fourth quarter 2025 compared to $3.9 million for the fourth quarter 2024 and $3.3 million for”
CV Sciences, Inc. amended convertible notes of aggregate outstanding principal amount of $2,256,000 with institutional investor.
“amounts of the Amended Notes were increased by 20% under the terms of the Notes. After such adjustment, the Amended Notes have an aggregate outstanding principal amount of $2,256,000. • True-Up Provision. The Amended Notes include a true-up provision designed to ensure that the net proceeds received by the Investor upon conversion and sale of the conversion”
CV Sciences, Inc. amended Agreement with an institutional investor ("Investor") valued at aggregate outstanding principal amount of $2,256,000 (effective 2026-03-04).
“On March 4, 2026, the Company and the Investor entered into an agreement (the “Agreement”) to, among other things, amend and restate the Amended Original Note and the Second Note”
CV Sciences, Inc. entered into Membership Interest Purchase Agreement with Elevated Softgels, LLC, Clayton J. Montgomery, Chris Fagan, Andrew Kester, Timothy McGreer valued at Cash payment of $100,000; issuance of 15,854,185 restricted shares valued at $637,000; issuance of 1 (effective 2024-05-08).
“On May 8, 2024, CV Sciences, Inc. (the “Company”), entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) by and among the Company, Elevated Softgels, LLC, a Delaware limited liability company (“Elevated Softgels”), Clayton J. Montgomery (a “Member”), Chris Fagan, Andrew Kester, and Timothy McGreer, pursuant to which the Company purchased all of the outstanding equity interests in Elevated Softgels, resulting in Elevated Softgels becoming a wholly owned subsidiary of the Company (the “Acquisition”).”
CV Sciences, Inc. reported for the quarter ended March 31, 2024 results: revenue $4.0 million.
“and products, today announced its financial results for the quarter ended March 31, 2024. First Quarter 2024 and Recent Financial and Operating Highlights • Generated revenue of $4.0 million for first quarter 2024 compared to $4.1 million for the first quarter 2023 and a sequential improvement from $3.8 million for the fourth quarter 2023; • Recognized gross margin”
CV Sciences, Inc. reported the fourth quarter of 2023 results: revenue $3.8 million.
“Revenue of $3.8 million for the fourth quarter 2023 compared to $4.1 million in the third quarter 2023;”
CV Sciences, Inc. reported fiscal year ended December 31, 2023 results: revenue $16.0 million.
“Generated revenue of $16.0 million for fiscal 2023 compared to $16.2 million for 2022;”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.